Latest & greatest articles for methylprednisolone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylprednisolone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylprednisolone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylprednisolone

21. Pulse methylprednisolone therapy in idiopathic, rapidly progressive glomerulonephritis.

Pulse methylprednisolone therapy in idiopathic, rapidly progressive glomerulonephritis. Pulse methylprednisolone therapy ... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1980 ) Volume: 92 , Issue: 4 , Pages: 504-506 PubMed: Available from or Find this paper at: Abstract Idiopathic crescentic glomerulonephritis is associated with a 70% to 80% incidence of end-stage renal failure. Oral (...) corticosteroid therapy in combination with immunosuppressive agents or anticoagulants has not altered the prognosis of this disease. We have seen five adults with idiopathic crescentic glomerulonephritis and treated them with intravenous methylprednisolone. Before therapy, the average serum creatinine concentration was 7.4 1.3 mg/dL (chi-square SEM). This value declined to 2.0 0.48 mg/dL within 4 weeks. All patients continue to maintain stable renal function over an average follow-up period of 19 months

Annals of Internal Medicine2013

22. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis

Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis 22128082 2012 05 08 2012 07 03 2013 11 21 1468-2060 71 6 2012 Jun Annals of the rheumatic diseases Ann. Rheum. Dis. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. 966-73 10.1136/annrheumdis-2011-200384 The objectives (...) of this study are to analyse the long-term follow-up of a randomised controlled trial of induction treatment with azathioprine/methylprednisolone (AZA/MP) versus high-dose intravenous cyclophosphamide (ivCY) in patients with proliferative lupus nephritis (LN) and to evaluate the predictive value of clinical, laboratory and renal biopsy parameters regarding renal outcome. 87 patients with biopsy-proven proliferative LN were treated with either AZA/MP (n=37) or ivCY (n=50), both with oral prednisone. After 2

EvidenceUpdates2012

23. Fungal Infections Associated with Contaminated Methylprednisolone in Tennessee.

Fungal Infections Associated with Contaminated Methylprednisolone in Tennessee. BACKGROUND: We investigated an outbreak of fungal infections of the central nervous system that occurred among patients who received epidural or paraspinal glucocorticoid injections of preservative-free methylprednisolone acetate prepared by a single compounding pharmacy. METHODS: Case patients were defined as patients with fungal meningitis, posterior circulation stroke, spinal osteomyelitis, or epidural abscess (...) with liposomal amphotericin B. Eight patients (12%) died, seven of whom had stroke. CONCLUSIONS: We describe an outbreak of fungal meningitis after epidural or paraspinal glucocorticoid injection with methylprednisolone from a single compounding pharmacy. Rapid recognition of illness and prompt initiation of therapy are important to prevent complications. (Funded by the Tennessee Department of Health and the Centers for Disease Control and Prevention.).

NEJM2012

24. Fungal Infections Associated with Contaminated Methylprednisolone Injections - Preliminary Report.

Fungal Infections Associated with Contaminated Methylprednisolone Injections - Preliminary Report. Fungal infections associated with contaminated methylprednisolone injections. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 (...) selected item: 23083312 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2013 Jun 27;368(26):2495-500. doi: 10.1056/NEJMra1212617. Epub 2012 Oct 19. Fungal infections associated with contaminated methylprednisolone injections. 1 , , . 1 Division of Infectious Diseases, Veterans Affairs Ann Arbor Healthcare System, University

NEJM2012

25. A Comparison Between Dexamethasone and Methylprednisolone for Vomiting Prophylaxis After Tonsillectomy in Inpatient Children: A Randomized Trial

A Comparison Between Dexamethasone and Methylprednisolone for Vomiting Prophylaxis After Tonsillectomy in Inpatient Children: A Randomized Trial 22798534 2012 09 24 2012 12 03 2016 10 25 1526-7598 115 4 2012 Oct Anesthesia and analgesia Anesth. Analg. A comparison between dexamethasone and methylprednisolone for vomiting prophylaxis after tonsillectomy in inpatient children: a randomized trial. 913-20 The frequent incidence of postoperative vomiting in children undergoing tonsillectomy (...) , in addition to the occurrence of severe pain, may delay postoperative oral intake and lead to increased risk of dehydration. Thus, prophylactic therapy is indicated in this high-risk group. Glucocorticoids, such as dexamethasone and methylprednisolone, have anti-inflammatory and antiemetic properties with dexamethasone being frequently used. We hypothesized that methylprednisolone should be noninferior to dexamethasone for the prevention of vomiting in children after tonsillectomy. We designed

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

26. Perioperative methylprednisolone and outcome in neonates undergoing heart surgery

Perioperative methylprednisolone and outcome in neonates undergoing heart surgery 22271697 2012 02 03 2012 03 27 2016 10 19 1098-4275 129 2 2012 Feb Pediatrics Pediatrics Perioperative methylprednisolone and outcome in neonates undergoing heart surgery. e385-91 10.1542/peds.2011-2034 Recent studies have called into question the benefit of perioperative corticosteroids in children undergoing heart surgery, but have been limited by the lack of placebo control, limited power, and grouping (...) of various steroid regimens together in analysis. We evaluated outcomes across methylprednisolone regimens versus no steroids in a large cohort of neonates. Clinical data from the Society of Thoracic Surgeons Database were linked to medication data from the Pediatric Health Information Systems Database for neonates (≤30 days) undergoing heart surgery (2004-2008) at 25 participating centers. Multivariable analysis adjusting for patient and center characteristics, surgical risk category, and within-center

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

27. Oral Methylprednisolone in Pediatric Acute Pyelonephritis Alleviates Renal Scarring

Oral Methylprednisolone in Pediatric Acute Pyelonephritis Alleviates Renal Scarring 21844061 2012 02 22 2012 04 23 2013 11 21 1098-4275 128 3 2011 Sep Pediatrics Pediatrics Adjunctive oral methylprednisolone in pediatric acute pyelonephritis alleviates renal scarring. e496-504 10.1542/peds.2010-0297 To determine if glucocorticoids can prevent renal scar formation after acute pyelonephritis in pediatric patients. Patients younger than 16 years diagnosed with their first episode of acute (...) pyelonephritis with a high risk of renal scar formation (ie, inflammatory volume ≥ 4.6 mL on technetium-99m-labeled dimercaptosuccinic acid scan [DMSA] or abnormal renal ultrasonography results) were randomly assigned to receive either antibiotics plus methylprednisolone sodium phosphate (1.6 mg/kg per day for 3 days [MPD group]) or antibiotics plus placebo (placebo group) every 6 hours for 3 days. Patients were reassessed by using DMSA 6 months after treatment. The primary outcome was the development

EvidenceUpdates2011

28. Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: a double-blind, placebo-controlled randomized trial

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: a double-blind, placebo-controlled randomized trial 21624649 2011 08 02 2011 10 24 2016 11 25 1097-6825 128 2 2011 Aug The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: a double-blind, placebo-controlled randomized trial. 348-52 10.1016/j.jaci (...) .2011.04.045 The place of systemic corticosteroids in the treatment of children with chronic rhinosinusitis (CRS) remains unclear. We sought to assess the effectiveness and tolerability of oral methylprednisolone as an anti-inflammatory adjunct in the treatment of CRS in children. Forty-eight children (age, 6-17 years) with clinically and radiologically proved CRS were included. Patients were randomly assigned to either oral amoxicillin/clavulanate (AMX/C) and methylprednisolone or AMX/C and placebo twice

EvidenceUpdates2011

29. Efficacy of periarticular injection of bupivacaine, fentanyl, and methylprednisolone in total knee arthroplasty:a prospective, randomized trial

Efficacy of periarticular injection of bupivacaine, fentanyl, and methylprednisolone in total knee arthroplasty:a prospective, randomized trial 20022457 2010 08 24 2010 12 16 2013 11 21 1532-8406 25 6 2010 Sep The Journal of arthroplasty J Arthroplasty Efficacy of periarticular injection of bupivacaine, fentanyl, and methylprednisolone in total knee arthroplasty:a prospective, randomized trial. 851-7 10.1016/j.arth.2009.09.007 We evaluated the efficacy of periarticular infiltration (...) Controlled Trial 2009 12 21 United States J Arthroplasty 8703515 0883-5403 0 Analgesics, Opioid 0 Anesthetics, Combined 0 Anesthetics, Local 0 Glucocorticoids UF599785JZ Fentanyl X4W7ZR7023 Methylprednisolone Y8335394RO Bupivacaine IM Aged Aged, 80 and over Analgesics, Opioid administration & dosage Anesthetics, Combined administration & dosage Anesthetics, Local administration & dosage Arthroplasty, Replacement, Knee Bupivacaine administration & dosage Female Fentanyl administration & dosage

EvidenceUpdates2010

30. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial 20542736 2010 07 08 2010 08 06 2015 11 19 1474-4465 9 7 2010 Jul The Lancet. Neurology Lancet Neurol Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group (...) trial. 672-80 10.1016/S1474-4422(10)70132-0 Interferon beta is commonly used to treat patients with relapsing-remitting multiple sclerosis; however, the treatment is only partially effective in reducing relapses and progression of disability. Corticosteroids are used to treat relapses in patients with multiple sclerosis. We therefore aimed to investigate the combination of cyclic methylprednisolone and interferon beta for the treatment of relapsing-remitting multiple sclerosis. In 2001, we designed

EvidenceUpdates2010

31. A double-blind randomised controlled study comparing subacromial injection of tenoxicam or methylprednisolone in patients with subacromial impingement

A double-blind randomised controlled study comparing subacromial injection of tenoxicam or methylprednisolone in patients with subacromial impingement 20044683 2010 01 01 2010 01 28 2016 11 25 2044-5377 92 1 2010 Jan The Journal of bone and joint surgery. British volume J Bone Joint Surg Br A double-blind randomised controlled study comparing subacromial injection of tenoxicam or methylprednisolone in patients with subacromial impingement. 77-82 10.1302/0301-620X.92B1.22137 We have carried out (...) a prospective double-blind randomised controlled trial to compare the efficacy of a single subacromial injection of the non-steroidal anti-inflammatory drug, tenoxicam, with a single injection of methylprednisolone in patients with subacromial impingement. A total of 58 patients were randomly allocated into two groups. Group A received 40 mg of methylprednisolone and group B 20 mg of tenoxicam as a subacromial injection along with lignocaine. The Constant-Murley shoulder score was used as the primary

EvidenceUpdates2010

32. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS

A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS 19949030 2009 12 01 2009 12 22 2015 11 19 1526-632X 73 22 2009 Dec 01 Neurology Neurology A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. 1842-8 10.1212/WNL.0b013e3181c3fd5b To compare the efficacy, tolerability, and safety of IV methylprednisolone (IV MP) vs oral methylprednisolone (oMP) at equivalent high doses in patients with multiple sclerosis (MS (...) over time (p < 0.001) without between-group difference at week 4. Both treatments were well-tolerated and adverse events were minimal and occurred similarly in the 2 treatment arms. Oral methylprednisolone (oMP) is as effective as IV methylprednisolone in reducing gadolinium-enhancing lesions in patients with MS soon after an acute relapse with similar clinical, safety, and tolerability profiles. This study provides class III evidence that 1 g oMP x 5 days is not inferior to 1 g IV MP x 5 days

EvidenceUpdates2010

33. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial

Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2008

34. Intravenous injection of methylprednisolone reduces the incidence of postextubation stridor in intensive care unit patients

Intravenous injection of methylprednisolone reduces the incidence of postextubation stridor in intensive care unit patients PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2008

35. Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.

Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. OBJECTIVE: To compare the effects of methotrexate (MTX), alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab, on magnetic resonance imaging (MRI)-detected synovitis, bone edema, and erosive changes in patients

EvidenceUpdates2008

37. 12-h pretreatment with methylprednisolone versus placebo for prevention of postextubation laryngeal oedema: a randomised double-blind trial.

12-h pretreatment with methylprednisolone versus placebo for prevention of postextubation laryngeal oedema: a randomised double-blind trial. 17398307 2007 04 02 2007 04 12 2015 06 16 1474-547X 369 9567 2007 Mar 31 Lancet (London, England) Lancet 12-h pretreatment with methylprednisolone versus placebo for prevention of postextubation laryngeal oedema: a randomised double-blind trial. 1083-9 The efficacy of corticosteroids in reducing the incidence of postextubation laryngeal oedema is (...) controversial. We aimed to test our hypothesis that methylprednisolone started 12 h before a planned extubation could prevent postextubation laryngeal oedema. We did a placebo-controlled, double-blind multicentre trial in 761 adults in intensive-care units. Patients who were ventilated for more than 36 h and underwent a planned extubation received intravenous 20 mg methylprednisolone (n=380) or placebo (381) 12 h before extubation and every 4 h until tube removal. The primary endpoint was occurrence

Lancet2007

38. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. BACKGROUND: Neuropsychiatric involvement in systemic lupus erythematosus is complex and several clinical presentations are related to this disease such as: convulsions, chronic headache, transverse myelitis, vascular brain disease, psychosis and neural cognitive dysfunction. This systematic review is an update of a review performed in 2000. OBJECTIVES: To assess the efficacy (...) and safety of cyclophosphamide and methylprednisolone in the treatment of neuropsychiatric manifestations of systemic lupus erythematosus. SEARCH STRATEGY: We searched EMBASE, LILACS, Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE up to and including May 2005. Additional articles were sought through handsearching in relevant journals. There were no language restrictions. SELECTION CRITERIA: All randomised controlled trials that compared cyclophosphamide to methylprednisolone were

Cochrane2006

39. Methylprednisolone was associated with an increase in death after head injury

Methylprednisolone was associated with an increase in death after head injury Methylprednisolone was associated with an increase in death after head injury | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylprednisolone was associated with an increase in death after head injury Article Text Treatment Methylprednisolone was associated with an increase in death after head injury Free Hilaire J Thompson , PhD , RN, CNRN , Asha Bakshi , MD Statistics from Altmetric.com No Altmetric data available

Evidence-Based Nursing (Requires free registration)2006

40. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. 14738791 2004 01 23 2004 03 05 2015 06 16 1474-547X 363 9404 2004 Jan 17 Lancet (London, England) Lancet Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. 192-6 Despite available treatment with intravenous immunoglobulin (IVIg), morbidity and mortality (...) are considerable in patients with Guillain-Barré syndrome (GBS). Our aim was to assess whether methylprednisolone, when taken with IVIg, improves outcome when compared with IVIg alone. We did a double-blind, placebo-controlled, multicentre, randomised study, to which we enrolled patients who were unable to walk independently and who had been treated within 14 days after onset of weakness with IVIg (0.4 g/kg bodyweight per day) for 5 days. We assigned 233 individuals to receive either intravenous

Lancet2004